Skip to main content

Advertisement

Log in

Botulinum Toxin for the Treatment of Movement Disorders

  • Movement Disorders (SA Factor, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

After botulinum toxin was initially used to treat strabismus in the 1970s, others started using it to treat movement disorders including blepharospasm, hemifacial spasm, cervical dystonia, spasmodic dysphonia, and oromandibular dystonia. It was discovered that botulinum toxin can be an effective treatment for focal movement disorders with limited side effects. Over the past three decades, various formulations of botulinum toxin have been developed and the therapeutic use of these toxins has expanded in movement disorders and beyond. We review the history and mechanism of action of botulinum toxin, as well as describe different formulations available and their potential therapeutic uses in movement disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm. 2008;115:559–65.

    Article  PubMed  CAS  Google Scholar 

  2. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–9.

    PubMed  CAS  Google Scholar 

  3. Tsui JK, Elsen A, Mak E, et al. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci. 1985;12:314–6.

    PubMed  CAS  Google Scholar 

  4. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347–50.

    Article  PubMed  CAS  Google Scholar 

  5. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987;2:237–54.

    Article  PubMed  CAS  Google Scholar 

  6. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167–93.

    Article  PubMed  CAS  Google Scholar 

  7. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics. 2010;4:325–32.

    PubMed  CAS  Google Scholar 

  8. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci. 1999;354:259–68.

    Article  PubMed  CAS  Google Scholar 

  9. Duchen LW. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci. 1971;14:47–60.

    Article  PubMed  CAS  Google Scholar 

  10. Holland RL, Brown MC. Nerve growth in botulinum toxin poisoned muscles. Neuroscience. 1981;6:1167–79.

    Article  PubMed  CAS  Google Scholar 

  11. Juzans P, Comella J, Molgo J, et al. Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle. Neuromuscul Disord. 1996;6(3):177–85.

    Article  PubMed  CAS  Google Scholar 

  12. de Paiva A, Meunier F, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200–5.

    Article  PubMed  Google Scholar 

  13. Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans. Muscle Nerve. 1994;17:1385–92.

    Article  PubMed  CAS  Google Scholar 

  14. Lange DJ, Brin MF, Warner CL, et al. Distant effects of local injection of botulinum toxin. Muscle Nerve. 1987;10:552–5.

    Article  PubMed  CAS  Google Scholar 

  15. Lange DJ, Rubin M, Greene PE, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve. 1991;14:672–5.

    Article  PubMed  CAS  Google Scholar 

  16. Girlanda P, Vita G, Nocolosi C, et al. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry. 1992;55:844–5.

    Article  PubMed  CAS  Google Scholar 

  17. Garner CG, Straube A, Witt TN, et al. Time course of distant effects of local injections of botulinum toxin. Mov Disord. 1993;8:33–7.

    Article  PubMed  CAS  Google Scholar 

  18. Filippi GM, Errico P, Santarelli R, et al. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113:400–4.

    Article  PubMed  CAS  Google Scholar 

  19. Rosales RL, Arimura K, Takenaka S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve. 1996;19:488–96.

    Article  PubMed  CAS  Google Scholar 

  20. Rosales RL, Dressler D. On muscle spindles, dystonia and botulinum toxin. Eur J Neurol. 2010;17:71–80.

    Article  PubMed  Google Scholar 

  21. Palomar FJ, Mir P. Neurophysiological changes after intramuscular injection of botulinum toxin. Clin Neurophysiol. 2012;123:54–60.

    Article  PubMed  CAS  Google Scholar 

  22. Boroff DA, Chen GS. On the question of permeability of the blood–brain barrier to botulinum toxin. Int Arch Allergy Appl Immunol. 1975;48:495–504.

    Article  PubMed  CAS  Google Scholar 

  23. Antonucci F, Rossi C, Gianfranceschi, et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28:3689–96.

    Article  PubMed  CAS  Google Scholar 

  24. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29:1761–8.

    Article  PubMed  Google Scholar 

  25. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord. 2004;19:S129–36.

    Article  PubMed  Google Scholar 

  26. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2003;49:34–8.

    Article  PubMed  CAS  Google Scholar 

  27. Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res. 2006;9:121–5.

    Article  PubMed  CAS  Google Scholar 

  28. Tintner R, Gross R, Winzer UF, et al. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005;65:765–7.

    Article  PubMed  CAS  Google Scholar 

  29. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213–7.

    Article  PubMed  CAS  Google Scholar 

  30. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743–6.

    Article  PubMed  CAS  Google Scholar 

  31. Jankovic J, Hunter C, Dolimbel BZ, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67:2233–5.

    Article  PubMed  CAS  Google Scholar 

  32. Dressler D, Munchau A, Bhatia KP, et al. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol. 2002;47:118–21.

    Article  PubMed  CAS  Google Scholar 

  33. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord. 1993;8:479–83.

    Article  PubMed  CAS  Google Scholar 

  34. Dressler D, Bigalke H, Benecke R. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol. 2003;250:967–9.

    Article  PubMed  CAS  Google Scholar 

  35. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186–8.

    Article  PubMed  CAS  Google Scholar 

  36. Kanovsky P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009;32:259–65.

    Article  PubMed  CAS  Google Scholar 

  37. Kanovsky P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011;43:486–92.

    Article  PubMed  Google Scholar 

  38. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19:S92–S100.

    Article  PubMed  Google Scholar 

  39. Goschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies–therapeutic consequences. Exp Neurol. 1997;147:96–102.

    Article  PubMed  CAS  Google Scholar 

  40. Dressler D, Dirnberger G, Bhatia KP, et al. Botulinum toxin antibody testing: comparison between the mouse protection assay and the mouse lethality assay. Mov Disord. 2000;15:973–6.

    Article  PubMed  CAS  Google Scholar 

  41. Palace J, Nairne A, Hyman N, et al. A radioimmuno-precipitation assay for antibodies to botulinum A. Neurology. 1998;50:1463–6.

    Article  PubMed  CAS  Google Scholar 

  42. Dressler D, Dirnberger G. Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol. 2001;45:257–60.

    Article  PubMed  CAS  Google Scholar 

  43. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999;66:612–6.

    Article  PubMed  CAS  Google Scholar 

  44. Kessler KR, Benecke R. The EBD test–a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord. 1997;12:95–9.

    Article  PubMed  CAS  Google Scholar 

  45. Dressler D, Bigalke H, Rothwell JC. The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans. J Neurol. 2000;247:630–2.

    Article  PubMed  CAS  Google Scholar 

  46. •• Simpson DM, Blitzer A, Brashera A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1699–706. This is a systematic review of the evidence for botulinum toxin treatment in various movement disorders.

    Article  PubMed  CAS  Google Scholar 

  47. Fahn S, List T, Moskowitz C, et al. Double-blind controlled study of botulinum toxin for blepharospasm. Neurology. 1985;35:271–2.

    Google Scholar 

  48. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616–23.

    Article  PubMed  CAS  Google Scholar 

  49. Truong D, Comella C, Fernandez HH, et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14:407–14.

    Article  PubMed  Google Scholar 

  50. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235:197–9.

    Article  PubMed  CAS  Google Scholar 

  51. Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A–Dysport and Botox–assuming a ratio of 4:1. Mov Disord. 1997;12:1013–8.

    Article  PubMed  CAS  Google Scholar 

  52. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–12.

    Article  PubMed  CAS  Google Scholar 

  53. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23:137–41.

    Article  PubMed  CAS  Google Scholar 

  54. Quagliato EM, Carelli EF, Viana MA. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol. 2010;33:27–31.

    PubMed  CAS  Google Scholar 

  55. Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve. 1992;15:1045–9.

    Article  PubMed  CAS  Google Scholar 

  56. Park YC, Lim JK, Lee DK, Yi SD. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci. 1993;8:334–40.

    PubMed  CAS  Google Scholar 

  57. Greene P, Kang U, Fahn S, et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990;40:1213–8.

    Article  PubMed  CAS  Google Scholar 

  58. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53:1439–46.

    Article  PubMed  CAS  Google Scholar 

  59. Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996;46:1066–72.

    Article  PubMed  CAS  Google Scholar 

  60. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998;64:13–7.

    Article  PubMed  CAS  Google Scholar 

  61. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (Botulinum Toxin Type B) in Type A-Resistant cervical dystonia. Neurology. 1999;53:1431–38.

    Article  PubMed  CAS  Google Scholar 

  62. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20:783–91.

    Article  PubMed  Google Scholar 

  63. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16:316–23.

    Article  PubMed  Google Scholar 

  64. Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308:103–9.

    Article  PubMed  CAS  Google Scholar 

  65. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6–12.

    Article  PubMed  CAS  Google Scholar 

  66. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65:1423–9.

    Article  PubMed  CAS  Google Scholar 

  67. Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord. 2008;23:510–7.

    Article  PubMed  Google Scholar 

  68. Brin MF, Blitzer A, Fahn S, et al. Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox). Mov Disord. 1989;4:287–96.

    Article  PubMed  CAS  Google Scholar 

  69. Blitzer A, Brin MF, Fahn S, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope. 1988;98:193–7.

    Article  PubMed  CAS  Google Scholar 

  70. Troung DD, Rontal M, Rolnick M, et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope. 1991;101:630–4.

    PubMed  CAS  Google Scholar 

  71. Adler CH, Bansberg SF, Krein-Jones K, Hentz JG. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord. 2004;19:1075–9.

    Article  PubMed  Google Scholar 

  72. Woodson G, Hochstetler H, Murry T. Botulinum toxin therapy for abductor spasmodic dysphonia. J Voice. 2006;20:137–43.

    Article  PubMed  Google Scholar 

  73. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 1998;108:1435–41.

    Article  PubMed  CAS  Google Scholar 

  74. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol. 1989;98:93–7.

    PubMed  CAS  Google Scholar 

  75. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53:633–9.

    Article  PubMed  CAS  Google Scholar 

  76. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53:2102–7.

    Article  PubMed  CAS  Google Scholar 

  77. Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16:438–41.

    Article  PubMed  Google Scholar 

  78. Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al. Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007;78:264–70.

    Article  PubMed  CAS  Google Scholar 

  79. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology. 1992;42:627–30.

    Article  PubMed  CAS  Google Scholar 

  80. Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer's cramp: a double-blind study. Neurology. 1993;43:183–5.

    Article  PubMed  CAS  Google Scholar 

  81. Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord. 1995;10:466–71.

    Article  PubMed  CAS  Google Scholar 

  82. Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol. 1996;53:617–24.

    Article  PubMed  CAS  Google Scholar 

  83. Lungu C, Karp BI, Alter K, et al. Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more. Mov Disord. 2011;26:750–3.

    Article  PubMed  Google Scholar 

  84. Schuele S, Jabusch HC, Lederman RJ, Altenmüller E. Botulinum toxin injections in the treatment of musician's dystonia. Neurology. 2005;64:341–3.

    Article  PubMed  CAS  Google Scholar 

  85. Pacchetti C, Albani G, Martignoni E, et al. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord. 1995;10:333–6.

    Article  PubMed  CAS  Google Scholar 

  86. Geenen C, Consky E, Ashby P. Localizing muscles for botulinum toxin treatment of focal hand dystonia. Can J Neurol Sci. 1996;23:194–7.

    PubMed  CAS  Google Scholar 

  87. Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology. 2002;58:805–7.

    Article  PubMed  CAS  Google Scholar 

  88. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11:250–6.

    Article  PubMed  CAS  Google Scholar 

  89. Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523–8.

    Article  PubMed  CAS  Google Scholar 

  90. Warrick P, Dromey C, Irish JC, et al. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope. 2000;110:1366–74.

    Article  PubMed  CAS  Google Scholar 

  91. Adler CH, Bansberg SF, Hentz JG, et al. Botulinum toxin type A for treating voice tremor. Arch Neurol. 2004;61:1416–20.

    Article  PubMed  Google Scholar 

  92. Wissel J, Masuhr F, Schelosky L, Ebersbach G, Poewe W, et al. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord. 1997;12:722–6.

    Article  PubMed  CAS  Google Scholar 

  93. Pahwa R, Busenbark K, Swanson-Hyland EF, et al. Botulinum toxin treatment of essential head tremor. Neurology. 1995;45:822–4.

    Article  PubMed  CAS  Google Scholar 

  94. Schneider SA, Edwards MJ, Cordivari C, et al. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease. Mov Disord. 2006;21:1722–4.

    Article  PubMed  Google Scholar 

  95. Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol. 2000;57:1190–3.

    Article  PubMed  CAS  Google Scholar 

  96. Marras C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001;56:605–10.

    Article  PubMed  CAS  Google Scholar 

  97. Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurol Sci. 2004;24:420–3.

    Article  PubMed  CAS  Google Scholar 

  98. Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord. 1996;11:431–3.

    Article  PubMed  CAS  Google Scholar 

  99. Trimble MR, Whurr R, Brookes G, Robertson MM. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord. 1998;13:617–9.

    Article  PubMed  CAS  Google Scholar 

  100. Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21:704–7.

    Article  PubMed  Google Scholar 

  101. Lagalla G, Millevolte M, Capecci M, et al. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009;256:563–7.

    Article  PubMed  CAS  Google Scholar 

  102. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62:37–40.

    Article  PubMed  CAS  Google Scholar 

  103. Chinnapongse R, Gullo K, Nemeth P, et al. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord. 2012;27:219–26.

    Article  PubMed  Google Scholar 

  104. Guidubaldi A, Fasano A, Ialongo T, et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord. 2011;26:313–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

We would like to thank Dr. Paul E. Greene for his helpful comments in revision of the manuscript.

Disclosure

Conflicts of interest: M.A. Thenganatt: is employed by Columbia University; and has received grant support from Parkinson’s Disease Foundation; S. Fahn: has been a consultant for Merz Pharmaceuticals and Impax Pharmaceuticals; is employed by Columbia University; has received grant support from Parkinson’s Disease Foundation; has received payment for lectures including service on speakers bureaus from Columbia University and Sun Pharma; receives royalties from a textbook (Principles and Practice of Movement Disorders).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mary Ann Thenganatt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thenganatt, M.A., Fahn, S. Botulinum Toxin for the Treatment of Movement Disorders. Curr Neurol Neurosci Rep 12, 399–409 (2012). https://doi.org/10.1007/s11910-012-0286-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-012-0286-3

Keywords

Navigation